Literature DB >> 10851203

Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans.

A Goette1, M Arndt, C Röcken, A Spiess, T Staack, J C Geller, C Huth, S Ansorge, H U Klein, U Lendeckel.   

Abstract

BACKGROUND: Previous studies have suggested that atrial fibrillation (AF) is associated with the activation of the atrial angiotensin system. However, it is not known whether the expression of angiotensin II receptors changes during AF. The purpose of this study was to determine the atrial expression of angiotensin II type 1 and type 2 receptors (AT(1)-R and AT(2)-R) in patients with AF. METHODS AND
RESULTS: Atrial tissue samples from 30 patients undergoing open heart surgery were examined. Eleven patients had chronic persistent AF (> or =6 months; cAF), 8 patients had paroxysmal AF (pAF), and 11 patients were in sinus rhythm. AT(1)-R and AT(2)-R were localized in the atrial tissue by immunohistochemistry and quantified at the protein and mRNA level by Western blotting and quantitative polymerase chain reaction. Both types of AT-R were predominantly expressed in atrial myocytes in all groups. The amount of AT(1)-R was reduced to 34.9% during cAF (P<0.01) and to 51.7% during pAF (P<0.05) compared with patients in sinus rhythm. In contrast, AT(2)-R was increased during cAF (246%; P=NS) and pAF (505%; P<0.01). AT(1)-R/AT(2)-R mRNA content was similar in all groups.
CONCLUSIONS: AF is associated with the down-regulation of atrial AT(1)-R and the up-regulation of AT(2)-R proteins. These findings may help define the pathophysiological role of the angiotensin system in the structural remodeling of the fibrillating atria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10851203     DOI: 10.1161/01.cir.101.23.2678

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  59 in total

Review 1.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 3.  [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].

Authors:  U Ravens; E Wettwer; U Schotten; R Wessel; D Dobrev
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

4.  [New aspects of atrial fibrillation therapy].

Authors:  U Ravens; D Dobrev; A Goette
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

Review 5.  [Atrial fibrillation].

Authors:  M G Hennersdorf; B E Strauer
Journal:  Internist (Berl)       Date:  2006-10       Impact factor: 0.743

6.  Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat.

Authors:  Marek Matus; Dana Kucerova; Peter Kruzliak; Adriana Adameova; Gabriel Doka; Katarina Turcekova; Jana Kmecova; Jan Kyselovic; Peter Krenek; Uwe Kirchhefer; Frank U Mueller; Peter Boknik; Jan Klimas
Journal:  Mol Cell Biochem       Date:  2015-02-08       Impact factor: 3.396

7.  Oxidative stress-mediated effects of angiotensin II in the cardiovascular system.

Authors:  Hairuo Wen; Judith K Gwathmey; Lai-Hua Xie
Journal:  World J Hypertens       Date:  2012-08-23

8.  Age-related atrial fibrosis.

Authors:  Felix Gramley; Johann Lorenzen; Christian Knackstedt; Obaida R Rana; Erol Saygili; Dirk Frechen; Sven Stanzel; Francesco Pezzella; Eva Koellensperger; Christian Weiss; Thomas Münzel; Patrick Schauerte
Journal:  Age (Dordr)       Date:  2008-10-07

Review 9.  The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias.

Authors:  Shahriar Iravanian; Samuel C Dudley
Journal:  Heart Rhythm       Date:  2008-03-04       Impact factor: 6.343

10.  Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxidative stress and adhesion molecules in patients with persistent atrial fibrillation.

Authors:  Andreas Goette; Alessandra D'Alessandro; Alicja Bukowska; Siegfried Kropf; Christian Mewis; Christoph Stellbrink; Jürgen Tebbenjohanns; Christian Weiss; Uwe Lendeckel
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.